Make in India: Can India be a hub for the $200 billion worth biosimilars opportunity

By HARI PULAKKAT, ET Bureau | Updated: Feb 18, 2016

The Indian generics industry got its first big break in 1984, when the US passed what is known as the Hatch-Waxman Act. With this legislation, the US streamlined the generic approvals, thereby making it easier for generic companies to compete in the US drug market. Observers of the pharmaceutical industry consider today's opportunity for India in biosimilars as not being different from that of the generics industry in 1984. Read more.....